Next Gen Virotherapy for GBM
Funded at Lsu Health Sciences Center · NIH-11578736 · Data updated 2026-11-12
A new treatment approach combines a herpes-based virus with a NOTCH-blocking strategy to tackle brain tumors called glioblastoma, aiming to be delivered safely inside the brain to improve how well it works without causing memory or safety problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lsu Health Sciences Center NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $515,810 |
| NIH project number | 7R01NS127473-05 |
| Project ID | NIH-11578736 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with glioblastoma who are candidates for intracranial virotherapy could potentially participate, pending eligibility and safety screening.
✕Less likely to help
Patients whose tumors do not respond to oncolytic virus therapy or who cannot tolerate intracranial delivery may not benefit.
What this research studies
This project explores using an oncolytic herpes simplex virus (oHSV) together with NOTCH pathway blockade to treat intracranial glioblastoma. Researchers will study how blocking specific NOTCH ligands affects virus therapy, tumor response, and safety in the brain, including potential effects on memory and neurogenesis. The work also looks at how NOTCH signaling in tumor-associated immune cells influences immune responses and the presence of suppressive cells that can limit benefit. By understanding these interactions, the study aims to optimize efficacy while reducing neurologic toxicity in patients with GBM.
Why it matters
Potential benefit: If successful, this approach could improve tumor control and extend survival for people with GBM while minimizing cognitive side effects.
How similar studies have gone: Previous work with oncolytic viruses and NOTCH-related strategies shows promise, but the specific combination and brain-delivery safety profile are still being tested.
Where this research is happening
-
Lsu Health Sciences Center
New Orleans, United States Active
Researchers
- Principal investigator: Kaur, Balveen — Lsu Health Sciences Center
- Study coordinator: Kaur, Balveen
Related research
Other NIH-funded projects on the same topics.
-
Development of a Cancer Research Core to Support HIV-related Malignancies in Africa
A program to build cancer research capacity in Africa to better prevent, diagnose, and treat HIV-related cancers like Kaposi sarcoma.
-
Data management and bio-specimen hub for KS research in Africa
A program hub in Africa and the U.S. will securely manage data and biospecimens to support research on AIDS-related Kaposi sarcoma and other HIV-associated cancers.
-
Finding hidden KS reservoirs to help people with AIDS-related cancer
A study aims to map where the Kaposi sarcoma–associated herpesvirus hides in the bodies of people living with HIV/AIDS to improve future treatments.
-
HIV-associated Kaposi sarcoma: improving care with ART and targeted treatment in EpKS
A patient-facing program exploring how standard HIV treatment plus cancer care can help people with epidemic Kaposi sarcoma in sub-Saharan Africa.
-
HIV-associated Kaposi sarcoma research in Africa and the US
A collaborative, international effort aims to better understand and improve care for Kaposi sarcoma in people living with HIV in Africa and the U.S.
-
Developmental Core for AIDS-related Malignancies in Africa
This grant supports training and capacity building to improve prevention, diagnosis, care, and treatment of AIDS-related cancers like Kaposi sarcoma in Africa, with opportunities for U.S. and African researchers to collaborate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.